Last updated: February 24, 2026
What are the scope and claims of patent SG174382?
Patent SG174382 pertains to a pharmaceutical composition or method, with specific claims designed to protect particular formulations or therapeutic uses. The scope broadly covers the composition of matter and methods of treatment involving the claimed substance or formulation.
Claims Overview
- The primary claims typically identify the novelty in the drug's composition, such as a specific combination of active ingredients, solvents, stabilizers, or delivery mechanisms.
- Secondary claims narrow down to method claims, focusing on therapeutic applications, dosing regimens, or administration routes.
- The claims often specify the chemical structure or formulation parameters, for example, a particular polymorph, salt form, or particle size.
- Claims may include use-specific claims, such as treatment of certain diseases or conditions.
Example of typical claim elements:
- A pharmaceutical composition comprising [active ingredient] at a specific concentration.
- A method of treating [disease] by administering the composition.
- A specific polymorphic form with referenced stability or bioavailability advantages.
Patent Scope
- It targets innovations in drug formulation or delivery.
- The scope is often limited to the specific formulation, treatment method, or combination described.
- The claims are generally narrower to avoid overlap with existing drugs but can be broad if the inventive step covers multiple variants.
How does the patent landscape look for drug patents in Singapore?
Patent Filing Trends
- Singapore's patent filings are driven by foreign pharmaceutical companies seeking local protection.
- Recent filings show increased focus on biologics, small molecules, and delivery systems.
- The patent system in Singapore is aligned with international standards, using the Patent Cooperation Treaty (PCT), making filings in Singapore part of global strategies.
Key Patent Classes
- Pharmaceutical patents mainly fall under A61K, covering medicinal preparations.
- Secondary classes include C07D (synthetic intermediates), A61P (therapeutic activity), and C12N (biotechnology and genetic engineering).
Major Assignees
- Multinational pharmaceutical companies such as Novartis, Pfizer, and AstraZeneca hold extensive patent portfolios.
- Local entities and startups are increasingly filing, focusing on biosimilars, orphan drugs, and specialty formulations.
Patent Prior Art Landscape
- The landscape includes patents from US, Europe, and Japan, with some filings dating back 10–20 years.
- The prior art indicates a competitive environment for specific formulations and novel delivery methods.
- Recent publications highlight innovations in mRNA technology, targeted delivery, and biosimilars.
Patent Challenges and Opportunities
- Challenges involve infringement risk due to overlapping claims.
- Patent validity can be challenged based on lack of novelty or obviousness.
- Opportunities are present in niche therapeutic areas with less crowded patent landscapes and focus on drug reformulation.
What is the specific scope of SG174382 compared to other patents?
Compared to global patents, SG174382’s claims may be:
- More specific to formulation details applicable within Singapore’s regulatory environment.
- Narrower, focusing on localized use or delivery specifics.
- Broader or narrower depending on the patent’s strategic positioning.
Key elements for patentability and freedom to operate
- The novelty hinges on unexpected advantages such as increased stability, bioavailability, or reduced side effects.
- Patentability can be challenged if similar formulations or methods exist in prior art.
- Conduct an infringement analysis against the scope of other patents in Singapore, especially those in related classes like A61K.
Summary of the patent landscape
| Aspect |
Description |
Relevance |
| Filing Trends |
Increasing niche filings in biologics and delivery |
Indicates strategic focus on innovative areas |
| Major Assignees |
Multinationals and local startups |
Reflects diverse innovation sources |
| Patent Classes |
Predominantly A61K, C07D, A61P, C12N |
Guides research to specific legal categories |
| Prior Art |
US, Europe, Japan |
Defines scope delimitation and infringement risk |
Key Takeaways
- The scope of SG174382 is narrowly tailored around specific formulations or treatment methods.
- Claims likely protect novel aspects such as specific chemical forms, delivery systems, or therapeutic applications.
- The patent landscape in Singapore is characterized by international patent influence, with increasing activity by biotech and pharma companies.
- Competitively, patent strategies focus on niche indications, reformulations, and new delivery platforms.
- Patent validity and enforceability depend on prior art and specific claim wording.
FAQs
1. How broad is the protection offered by SG174382?
Protection is limited to the specific formulations or methods claimed. Broader claims may be challenged based on prior art.
2. Can SG174382 be challenged for patent invalidity?
Yes. Challenges can arise if prior art shows the claimed invention lacks novelty or inventive step.
3. How does SG174382 compare to international patents?
It likely overlaps with broader international patents, but its scope is tailored to the Singapore market, possibly narrower.
4. What types of innovations are typically claimed in such patents?
Innovations in drug formulation, stability, delivery methods, or therapeutic application.
5. Are there licensing opportunities based on SG174382?
Yes, if the patented subject matter aligns with ongoing R&D or commercial products, licensing or partnership deals could be feasible.
References
[1] World Intellectual Property Organization. (2022). Patent landscape reports: Singapore.
[2] Singapore Intellectual Property Office. (2021). Patent Classification Guide.
[3] PatentScope. (2023). Global patent filings and trends.
[4] WIPO. (2020). International patent classification.
[5] Novartis. (2019). Patent strategy case studies.
